Core Insights - Argenx SE has discontinued its Phase 3 UplighTED studies for efgartigimod SC in adults with moderate to severe thyroid eye disease due to futility, as advised by an Independent Data Monitoring Committee [1][2] - The company plans to conduct a comprehensive analysis of the data post-study closure to inform future research in thyroid eye disease [2] - Despite this setback, Argenx remains committed to advancing its portfolio of novel antibody-based medicines and exploring therapies for serious autoimmune conditions [3] Financial Overview - Argenx's stock has experienced fluctuations, with a recent price target set at $1,248 by Stifel Nicolaus, indicating a potential increase of approximately 40.26% from the current price of $849.52 [4] - The stock has seen a decrease of about 3.24% or $28.43 recently, with a trading range between $827.52 and $853.96 during the day [4] - Over the past year, the stock reached a high of $934.62 and a low of $510.06, with a market capitalization of approximately $51.96 billion [5]

Core Insights - Argenx SE has decided to discontinue the Phase 3 UplighTED studies for efgartigimod in adults with moderate to severe thyroid eye disease (TED) based on an Independent Data Monitoring Committee's recommendation due to futility [1][3] Study Design and Outcomes - The Phase 3 studies aimed to evaluate the efficacy, safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of efgartigimod PH20 SC in adult participants with TED, with the primary endpoint being the percentage of participants who were proptosis responders at week 24 [4] - Key secondary endpoints included changes in proptosis measurement, total Graves' Orbitopathy Quality of Life (GO-QoL) score, and the percentage of participants with resolution of diplopia at week 24 [5] Safety Profile - Efgartigimod demonstrated a favorable safety and tolerability profile, with no new safety signals identified during the trials [2] Market Implications - The discontinuation of the studies raises questions about the biological differences between TED and related conditions, as noted by analysts [6] - Amgen's Tepezza is currently the only FDA-approved drug for TED, while Viridian Therapeutics' veligrotug is expected to receive FDA approval in 2026 [7] - Analyst projections for peak TED sales for Vyvgart are estimated at $550 million, assuming a 60% probability of success, indicating a secondary opportunity compared to larger programs [7] - Following the news, Argenx shares fell by 4.86% to $835.31 [8]

Group 1 - U.S. stock futures are higher, with Dow futures gaining around 200 points [1] - Argenx SE shares fell 6% to $825.00 in pre-market trading after discontinuing Phase 3 studies of efgartigimod SC in thyroid eye disease [1] Group 2 - TryHard Holdings Ltd shares tumbled 15.2% to $13.16 in pre-market trading after a previous jump of 58% [2] - Site Centers Corp declined 13.4% to $6.33 in pre-market trading [2] - Exicure Inc dipped 8.7% to $5.80 in pre-market trading after gaining 5% on Friday [2] - Celldex Therapeutics Inc declined 8.4% to $25.19 in pre-market trading [2] - CapsoVision Inc fell 6.4% to $12.03 in pre-market trading after a decline of around 11% on Friday [2] - Zillow Group Inc fell 5.6% to $70.50 in pre-market trading [2] - BeOne Medicines AG declined 4.9% to $303.50 in pre-market trading [2] - ServiceNow Inc fell 4.7% to $824.50 in pre-market trading after a downgrade to Underweight by KeyBanc [2] - WaterBridge Infrastructure LLC fell 4.4% to $20.05 in pre-market trading [2] - Pharming Group N V declined 4.2% to $17.23 in pre-market trading [2]

Group 1 - U.S. stock futures are higher, with Dow futures gaining around 200 points [1] - Argenx SE shares fell 6% to $825.00 in pre-market trading after discontinuing Phase 3 studies of efgartigimod SC in thyroid eye disease [1] Group 2 - TryHard Holdings Ltd shares tumbled 15.2% to $13.16 in pre-market trading after a previous jump of 58% [2] - Site Centers Corp declined 13.4% to $6.33 in pre-market trading [2] - Exicure Inc dipped 8.7% to $5.80 in pre-market trading after gaining 5% on Friday [2] - Celldex Therapeutics Inc declined 8.4% to $25.19 in pre-market trading [2] - CapsoVision Inc fell 6.4% to $12.03 in pre-market trading after a decline of around 11% on Friday [2] - Zillow Group Inc fell 5.6% to $70.50 in pre-market trading [2] - BeOne Medicines AG declined 4.9% to $303.50 in pre-market trading [2] - ServiceNow Inc fell 4.7% to $824.50 in pre-market trading after a downgrade to Underweight by KeyBanc [2] - WaterBridge Infrastructure LLC fell 4.4% to $20.05 in pre-market trading [2] - Pharming Group N V declined 4.2% to $17.23 in pre-market trading [2]

Market Movements - US stock index futures are all up, with Dow futures rising by 0.47%, S&P 500 futures up by 0.50%, and Nasdaq futures also increasing by 0.50% [1] - European indices are also showing positive movements, with Germany's DAX up by 0.44%, UK's FTSE 100 up by 0.94%, France's CAC40 up by 1.13%, and the Euro Stoxx 50 up by 0.74% [1] Commodity Prices - WTI crude oil has decreased by 0.42%, trading at $57.00 per barrel, while Brent crude oil has fallen by 0.41%, priced at $60.87 per barrel [2] Economic News - The market is focused on the potential candidates to succeed Jerome Powell as the next Federal Reserve Chair, with President Trump suggesting Kevin Hassett or Kevin Warsh [3] - Key economic data, including the November employment report and CPI data, are set to be released this week, following a recent 25 basis point rate cut by the Fed [3][4] - The bond market is engaged in intense discussions regarding the Fed's future rate cuts, with expectations of two rate cuts next year despite persistent inflation [4] Company News - iRobot has filed for Chapter 11 bankruptcy protection, indicating that existing common stockholders will not receive any equity in the restructured company [6][7] - STMicroelectronics is expected to deliver over 5 billion Starlink chips in the next two years, reflecting the growing demand in the commercial space sector [7] - Sanofi's multiple sclerosis drug tolebrutinib faces delays in FDA approval and has failed in a late-stage trial, potentially threatening its projected $1.7 billion annual sales peak [8] - Argenx has terminated its trial for a thyroid eye disease drug based on recommendations from an independent data monitoring committee, impacting its treatment goals [8] - Rocket Lab has successfully executed its first dedicated launch mission for JAXA, marking a significant milestone for the company in the commercial space sector [9]

Core Viewpoint - Argenx SE has decided to terminate the late-stage trial of its experimental drug Efgartigimod (brand name Vyvgart) for treating autoimmune diseases affecting the eyes, leading to a significant drop in its stock price, marking the largest decline in seven months [1]. Group 1: Trial Termination Impact - The independent data monitoring committee recommended stopping the trial for Efgartigimod in adult patients with moderate to severe thyroid eye disease, which has implications for the company's goal of treating 50,000 patients by 2030 [1]. - The stock price of Argenx fell by 9.7% on the Brussels stock exchange, the largest drop since May 8, and was down 5.31% in pre-market trading in the U.S. [1]. - The termination of the trial excludes a potential market of approximately 100,000 patients in the U.S. [1]. Group 2: Future Prospects and Analyst Opinions - Argenx plans to announce results from four other late-stage clinical trials for various autoimmune diseases next year, three of which involve Vyvgart [1]. - Despite the setback, some analysts maintain a positive long-term outlook for Argenx, viewing the emotional sell-off as a buying opportunity for a key European biotech stock [3]. - The drug Vyvgart has shown good safety and tolerability characteristics, with no new safety signals reported, and is already approved for treating generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy [2].

Market Overview - U.S. stock futures are up early Monday morning, following a mixed week with a rotation from expensive tech stocks to value stocks, despite a third consecutive interest rate cut [1] - The 10-year Treasury bond yielded 4.17%, while the two-year bond was at 3.51%, with a 73.4% likelihood of the Federal Reserve keeping interest rates unchanged in the upcoming meeting [3] Stocks in Focus - iRobot Corp. is down 81.98% pre-market after filing for bankruptcy due to tariffs impacting margins [5] - MindWalk Holdings is expected to report a loss of $0.01 per share on $4 million in revenue, with the stock up 10.73% pre-market [5] - Katapult Holdings is down 9.12% pre-market following an all-stock merger announcement, with poor momentum scores [5] Economic Data and Events - The Empire State Manufacturing Survey results are anticipated, along with speeches from Federal Reserve officials [2][12] - Upcoming economic data includes the home builder confidence index and various economic indicators throughout the week [12] Commodity and Crypto Markets - Crude oil futures are trading higher by 0.31% at approximately $57.42 per barrel, while gold is up 1.10% at around $4,346.35 per ounce [10] - Bitcoin is trading 1.90% higher at $89,848.10 per coin [10]

Market Overview - U.S. stock futures are up early Monday morning, following a mixed week with a rotation from expensive tech stocks to value stocks, despite a third consecutive interest rate cut [1] - The 10-year Treasury bond yielded 4.17%, while the two-year bond was at 3.51% [3] - The CME Group's FedWatch tool indicates a 73.4% likelihood of the Federal Reserve keeping interest rates unchanged at its next meeting on January 28, 2026 [3] Stocks in Focus - iRobot Corp. is down 81.98% pre-market after filing for bankruptcy due to tariffs impacting margins [5] - MindWalk Holdings is expected to report a loss of $0.01 per share on $4 million in revenue, with the stock up 10.73% pre-market [5] - Katapult Holdings is down 9.12% pre-market following news of an all-stock merger with Aaron's and CCF [5] - Argenx SE is down 6.72% pre-market after discontinuing its Phase 2 studies for thyroid eye disease [4] Economic Data and Events - The Empire State Manufacturing Survey results are anticipated, along with speeches from Federal Reserve officials [2][12] - Upcoming economic data includes the home builder confidence index from the National Association of Home Builders [12] Commodity and Crypto Markets - Crude oil futures are trading higher by 0.31% at approximately $57.42 per barrel [10] - Gold Spot is up 1.10%, hovering around $4,346.35 per ounce [10] - Bitcoin is trading 1.90% higher at $89,848.10 per coin [10]

Group 1 - U.S. stock futures are trading higher, indicating potential investor interest in various stocks [1] - MindWalk Holdings Corp. (NASDAQ:HYFT) is expected to report a quarterly loss of $0.01 per share on revenue of $4.00 million, with shares falling 5.4% to close at $1.77 [1] - Argenx SE (NASDAQ:ARGX) has discontinued Phase 3 UplighTED studies of Efgartigimod SC in thyroid eye disease after a futility review, leading to a 1.3% drop in shares to close at $877.94 [1] - Navan Inc. (NASDAQ:NAVN) is anticipated to post a quarterly loss of $0.25 per share on revenue of $182.04 million, with shares gaining 4.53% to $14.55 [1] - AMREP Corp. (NYSE:AXR) reported disappointing second-quarter results, with earnings of $0.22 per share and sales of $9.398 million, both missing analyst estimates, resulting in a 4.1% decline in shares to $20.16 [1] - Champions Oncology Inc. (NASDAQ:CSBR) is expected to report quarterly earnings of $0.01 per share on revenue of $14.04 million, with shares surging 6.3% to close at $6.72 [1]

Core Viewpoint - argenx SE has announced the discontinuation of the Phase 3 UplighTED studies evaluating efgartigimod for moderate to severe thyroid eye disease (TED) based on an Independent Data Monitoring Committee's recommendation due to futility [1][2] Group 1: Study Discontinuation - The Phase 3 UplighTED studies were halted after an interim analysis indicated that the trials did not meet the desired outcomes [2][3] - The decision reflects a responsible evaluation of the study's future likelihood of success, emphasizing the company's commitment to disciplined resource management [3] Group 2: Study Design and Objectives - The UplighTED studies were randomized, double-masked, placebo-controlled trials designed to assess the efficacy, safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of efgartigimod in adults with active, moderate-to-severe TED [4] - The primary endpoint was the percentage of participants who were proptosis responders at week 24, with key secondary endpoints including changes in proptosis measurement and quality of life scores [4] Group 3: Background on Thyroid Eye Disease - Thyroid Eye Disease (TED) is an autoimmune condition associated with Graves' disease and characterized by symptoms such as proptosis, diplopia, and potential vision loss, significantly impacting patient quality of life [5] Group 4: About Efgartigimod - Efgartigimod is a human IgG1 antibody fragment that reduces circulating IgG autoantibodies and is the first approved FcRn blocker for various autoimmune diseases [6]